Abstract
Streptozotocin-induced diabetes leads to the development of endothelial dysfunction, as evidenced by decreased expression of endothelial nitric oxide synthase (eNOS) and increased expression of endothelin-1 as specific markers of endothelial disorders. All test substances showed endotelioprotective activity by increasing the concentration of eNOS and reducing the level of endothelin-1. With respect to the degree of impact on the eNOS and endothelin-1 levels, the compounds studied can be rated as follows: sulodexide > meksidol.
MeSH terms
-
Animals
-
Biomarkers / metabolism
-
Blood Glucose
-
Diabetes Mellitus, Experimental / chemically induced
-
Diabetes Mellitus, Experimental / metabolism
-
Endothelin-1 / immunology
-
Endothelin-1 / metabolism*
-
Endothelium / drug effects*
-
Endothelium / metabolism
-
Endothelium / physiopathology
-
Glycosaminoglycans / pharmacology*
-
Immunohistochemistry
-
Male
-
Nitric Oxide Synthase Type III / immunology
-
Nitric Oxide Synthase Type III / metabolism*
-
Picolines / pharmacology*
-
Rats
-
Vascular Diseases / metabolism
Substances
-
Biomarkers
-
Blood Glucose
-
Endothelin-1
-
Glycosaminoglycans
-
Picolines
-
emoxypine succinate
-
glucuronyl glucosamine glycan sulfate
-
Nitric Oxide Synthase Type III